biote Management
Management criteria checks 1/4
biote's CEO is Bret Christensen, appointed in Feb 2025, has a tenure of less than a year. directly owns 0.12% of the company’s shares, worth $145.18K. The average tenure of the management team and the board of directors is 1.8 years and 3.6 years respectively.
Key information
Bret Christensen
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | less than a year |
| CEO ownership | 0.1% |
| Management average tenure | 1.8yrs |
| Board average tenure | 3.6yrs |
Recent management updates
Recent updates
Restructuring At Biote Will Drive Greater Growth And Profitability
Sep 10Results: biote Corp. Exceeded Expectations And The Consensus Has Updated Its Estimates
Aug 09
Benign Growth For biote Corp. (NASDAQ:BTMD) Underpins Stock's 28% Plummet
Aug 08biote Corp. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
May 10Market Participants Recognise biote Corp.'s (NASDAQ:BTMD) Earnings
May 09biote Corp. (NASDAQ:BTMD) Soars 26% But It's A Story Of Risk Vs Reward
Dec 02Market Cool On biote Corp.'s (NASDAQ:BTMD) Revenues
Sep 27
Biote's Innovative Strategies And Expansions Set To Enhance Revenue And Shareholder Value
Expanding the practitioner network and launching BioteRx aim to uniquely position the company in the wellness market, possibly boosting revenue through differentiated service offerings.biote initiated as a buy at Truist on leadership in hormone optimization; sees 138% upside
Sep 27Biote partners with IMAC Holdings
Sep 07CEO
Bret Christensen (54 yo)
Mr. Bret Christensen is Director of Neurolutions, Inc. (also known as Kandu, Inc.) from October 2025. Mr. Christensen serves as CEO & Director of biote Corp. since February 1, 2025. He served as Chief Exec...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CFO and Chief Business Officer | 1.9yrs | US$1.77m | no data | |
| CEO & Director | less than a year | no data | 0.12% $ 145.2k | |
| Chief Information Officer | 1.7yrs | no data | no data | |
| VP of Business Development | 4.5yrs | US$1.05m | no data | |
| Chief Marketing Officer | less than a year | no data | no data | |
| Chief Digital Officer | 4.9yrs | no data | no data | |
| Head of Nutraceuticals | 3.6yrs | no data | no data | |
| Chief Clinical Advisor & Member of Medical Advisory Board | no data | no data | no data | |
| SVP of Strategy & Commercial Operations | less than a year | no data | no data |
Experienced Management: BTMD's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | less than a year | no data | 0.12% $ 145.2k | |
| Chief Clinical Advisor & Member of Medical Advisory Board | no data | no data | no data | |
| Independent Director | 3.6yrs | US$275.10k | 7.68% $ 9.6m | |
| Non-Executive Chairman of the Board | 4.9yrs | US$2.68m | 0.33% $ 416.3k | |
| Independent Director | 3.1yrs | US$261.83k | 0.16% $ 193.7k | |
| Director | less than a year | no data | no data | |
| Chair of Medical Advisory Board | no data | no data | no data | |
| Independent Director | 4.3yrs | US$260.62k | 0.50% $ 621.1k | |
| Independent Director | 3.6yrs | US$272.69k | 0.20% $ 247.0k | |
| Senior Medical Advisor & Member of Medical Advisory Board | no data | no data | no data | |
| Member of Medical Advisory Board | no data | no data | no data | |
| Member of Medical Advisory Board | no data | no data | no data |
Experienced Board: BTMD's board of directors are considered experienced (3.6 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/24 22:42 |
| End of Day Share Price | 2025/12/24 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
biote Corp. is covered by 6 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jeffrey Van Sinderen | B. Riley Securities, Inc. |
| Kaumil Gajrawala | Jefferies LLC |
| George Kelly | Roth Capital Partners |